The State of America's Direct Support Workforce Crisis 2026
New data reveal little sign of meaningful progress ahead of impending wave of funding cuts.
Explore the Research
May 26, 2022
Webinar[FROM PLATINUM PARTNER JAZZ PHARMACEUTICALS] EPIDIOLEX® in the Long Term Care Setting
Share this page
Stay Informed on the Latest Research & Analysis from ANCOR
More Training & Events
March 11, 2025
Partner PresentationSymposium Spotlight: Bipolar, Seizures, Anxiety, and Their Treatments
November 21, 2024
Partner PresentationManning the Crow’s Nest: Using Relevant Metrics and KPIs to Drive Achievement of Agency Objectives
ANCOR Platinum Partner Jazz Pharmaceuticals has developed EPIDIOLEX, the first and only FDA approved cannabinoid designed specifically to address seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, and Tuberous Sclerosis Complex (TSC).